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ABSTRACT
Objective:We evaluated Novasure ablation as a mechan-
ical endometrial preparation agent before Roller Ball en-
dometrial ablation in lieu of GnRH agonists in large uteri.
Methods: A retrospective chart review of 20 consecutive
patients undergoing Novasure ablation for mechanical
endometrial preparation before Roller Ball ablation (RB-
Novasure group) was conducted and the results com-
pared to that of 23 consecutive patients who received
GnRH agonist (Leuprolide acetate) as a medical endome-
trial preparation before Roller Ball ablation (RB-Lupron
group). The postoperative follow-up time frame was di-
vided into immediate (3 mo), intermediate (3 to 12 mo)
and long-term (12 to 32 mo). Rates of amenorrhea, heavy
bleeding, cramping, and failure (repeat ablation or hys-
terectomy for heavy bleeding or persistent pain) were
compared between the 2 groups.
Results: The mean rates of amenorrhea for the patients
not lost to follow-up at 3 mo, 3 to 12 mo, and 12 to 32 mo
visits were 45.5%, 58.8%, and 44.4% for the RB-Lupron
group, and 80%, 86.7%, and 100% for the RB-Novasure
group (P  .02, P  .08, and P  .02). Failure rates were
4.8%, 6.2%, and 55.6% for the RB-Lupron group; and 0
(0/20), 12.5% (2/16) and 0 (0/8) for the RB-Novasure
group (P  .51, P  .50, and P  .02). The RB-Novasure
group had a significantly lower rate of heavy bleeding and
cramping. 86.4%, 58.8%, and 33.3% patients reported sat-
isfaction with their treatment in the RB-Lupron group and
100%, 87.5%, and 75% in RB-Novasure group (P  .13,
P  .07, and P  .11).
Conclusion: Novasure ablation, for mechanical endome-
trial preparation before Roller Ball ablation, appears to be
a superior alternative to medical preparation with GnRH
agonists in patients with large uteri.
Key Words: Endometrial ablation, GnRH agonist, Men-
orrhagia, Novasure, Roller Ball.
INTRODUCTION
Menorrhagia is a major cause of morbidity among women.
Although various definitions for menorrhagia exist with
varying degrees of blood loss (60cc to 80cc) per menstru-
ation, recent recommendations suggest that menorrhagia
should be defined as “excessive menstrual blood loss,
which interferes with the woman’s physical, emotional,
social, and material quality of life, and which can occur
alone or in combination with other symptoms.”1 World-
wide, there are approximately 19% of women of repro-
ductive age suffering from menorrhagia.2 It is the most
common reason for gynecologic office visits in the United
States.3 For women refractory to medical treatment for
menorrhagia, endometrial ablation is an alternative to
hysterectomy. Studies have shown that endometrial abla-
tion, compared to hysterectomy, is associated with faster
patient recovery, shorter hospital stay, earlier return to
work, fewer complications, and reduced costs.4-6
A recent Cochrane review concluded that success rates
and complication profiles of newer nonhysteroscopic
global ablation techniques involving heated fluid, thermal
balloon, radio frequency, microwave energy, or cryother-
apy compared favorably with first-generation transcervical
hysteroscopic methods, such as resection and ablation
procedures (laser, loop resection, Roller Ball cautery).7
However, in our clinical experience, nonhysteroscopic
devices alone had a higher failure rate with larger uteri
(not enough area ablated) and fibroid uteri (distorting the
cavity and limiting the ablation). In these cases, the only
option, other than hysterectomy, is to resort back to tran-
scervical hysteroscopic ablation. In this process, most hys-
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teroscopic ablative procedures, like Roller Ball, are able to
destroy 4 mm to 6 mm of the endometrium and preoper-
ative endometrial preparation before ablation aids by
making the endometrial lining thinner. A Cochrane review
of preoperative endometrial thinning agents, prior to an
ablative procedure, showed GnRH agonists to be superior
to both danazol and progesterone.8 However, medical
endometrial preparation, particularly with GnRH analogs,
is associated with adverse effects, considerable wait pe-
riod prior to ablation, and significant cost.
We therefore resorted to performing mechanical endome-
trial preparation as an alternative to medical endometrial
preparation. Since simple curettage of the endometrium
leads to visualization problems for the subsequent hyster-
oscopic ablation, we evaluated Novasure as a means of
mechanical endometrial preparation before Roller-Ball
endometrial ablation in place of GnRH agonists.
MATERIALS AND METHODS
We reviewed the charts of 20 consecutive patients who
underwent Novasure ablation as mechanical endometrial
preparation before Roller Ball ablation (RB-Novasure
group) performed by a single surgeon. We also reviewed
the charts of 23 consecutive patients who received GnRH
agonist (Leuprolide acetate) as medical endometrial prep-
aration before Roller Ball ablation performed by the same
surgeon (RB-Lupron group). The RB-Lupron group served
as the control group. This pilot study was conducted at
Temple University Hospital at Philadelphia after obtaining
Institutional Review Board approval. All patients had large
uteri, defined as uterine volume  200cc,3,9 normal Papa-
nicolaou test within the past year, and normal preopera-
tive endometrial biopsy. Demographic data, indication for
ablation, postoperative symptoms, and information about
whether the patient had reablation or hysterectomy were
collected.
Patients undergoing medical preparation of the endome-
trium received a single dose of Leuprolide acetate (Lu-
pron) 11.25 mg approximately 1 to 3 mo before the sched-
uled ablation with Roller Ball. The mechanical preparation
group underwent Novasure, followed by Roller Ball abla-
tion of the endometrium in the same sitting. Roller Ball
ablation in both groups was performed in standard fash-
ion, by using 1.5% glycine as the distention medium and
electrocautery set at 100 cutting and 100 coagulation.
The postoperative follow-up time frame was divided into
immediate (3 mo), intermediate (3 to 12 mo), and long-term
(12 to 32 mo) groups. A survey was also mailed to all the
patients regarding their postoperative symptoms. Amenor-
rhea was defined as the complete absence of bleeding, and
“heavy bleeding” as bleeding heavier than that before sur-
gery. Cramping was defined as lower abdominal or pelvic
pain affecting the activities of daily living. The patient was
also asked to comment on whether she was satisfied or
not with the treatment. Failure of the procedure was
considered if the patient underwent a repeat ablation or
hysterectomy for heavy bleeding or persistent pain. Data
were entered into an Excel spreadsheet (MS Excel, Mi-
crosoft, Richmond USA) and analyzed using SPSS (SPSS
Inc, Version 16 for Mac OS X).
RESULTS
A total of 43 patients were included in the study. Twenty-
three (53.5%) underwent Roller Ball ablation with Leupro-
lide acetate endometrial preparation (RB-Lupron), and 20
(46.5%) patients underwent Roller Ball ablation with No-
vasure endometrial preparation (RB-Novasure). The base-
line characteristics of the cohort are described in the Table 1.
A comparison of means established that both the groups
were comparable. The reasons for large uteri in both
groups are described in Table 2.
The rate of follow-up at 3, 3 to 12 and 12 to 32 mo was
100%, 77% and 41% for the RB-Lupron group and 100%,
75%, and 40% for the RB-Novasure group. The results of
amenorrhea, heavy bleeding, cramping or pelvic pain,
satisfaction and failure rates for both groups are summa-
rized in Table 3. The group with Novasure as an endo-
metrial preparatory agent (RB-Novasure) showed a signif-
icantly higher amenorrhea rate at 3, 3 to 12, and 12 to 32
mo intervals. For the patients not lost to follow-up, the
mean rates of amenorrhea were 45.5%, 58.8%, and 44.4%,
respectively, for the RB-Lupron group, and 80%, 86.7%,
and 100% for the RB-Novasure group (P  .02, P  .08,
and P .02) (Figure 1). The RB-Novasure group also had
a lower rate of heavy bleeding and significantly lower
cramping or pelvic pain at all 3 time intervals (Table 3).
Patient-reported satisfaction rates at all 3 time-intervals
were 86.4%, 58.8%, and 33.3% for the RB-Lupron group,
and 100%, 87.5%, and 75% with the RB-Novasure group
(P  .13, P  .07, and P  .11) (Figure 2). Failure rates
(defined as repeat ablative procedure or hysterectomy for
heavy bleeding or persistent pain) were 4.8%, 6.2%, and
55.6% for the RB-Lupron group; and 0 (0/20), 12.5% (2/
16), and 0 (0/8) for the RB-Novasure group (P  .51, P 
.50 and P  .02) at 3, 3 to 12, and 12 to 32 mo intervals,
respectively (Figure 3).
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There was 1 uterine perforation, 1 difficult extubation in
the RB-Lupron group, and 2 cases of false passage (de-
fined as partial entry of dilator into the myometrium) in
the RB-Novasure group.
DISCUSSION
This study presents a novel concept of using Novasure for
endometrial preparation before Roller Ball ablation. In
patients with large uteri, Novasure, as a mechanical
method of endometrial preparation, appears to be more
effective than medical endometrial preparation with Leu-
prolide acetate before Roller Ball ablation. Overall, the
RB-Novasure group had higher rates of persistent amen-
orrhea, lesser rates of heavy bleeding, cramping, pelvic
pain, and failure. Patients in the RB-Novasure group also
reported higher satisfaction, compared to the RB-Lupron
group.
Novasure, as a mechanical endometrial preparation agent,
thus has several advantages over the GnRH agonists.
When mechanical endometrial preparation is done with
Novasure, Roller Ball ablation can be scheduled sooner,
without a typical delay of 30 d to 90 d involved with
medical endometrial preparation. Although our study did
not address the issue of side effects, the typically reported
side effects of GnRH agonist (Leuprolide acetate), such as
headache, depression, insomnia, fatigue, dizziness/ver-
tigo, skin reaction, hot flashes, decreased libido, nausea/
vomiting, altered bowel function, weight gain/loss, vagi-
nitis, and urinary symptoms10 can be eliminated when
Novasure is used.
Novasure, in addition to Roller Ball, increased the overall
mean operative time by only 5 min; hence, it did not
significantly increase operating room costs. Also, the cost
of a Novasure is $600 per device, which is significantly
lower than the cost of the GnRH agonist (Leuprolide
acetate)11 of $2,073 dollars per dose.
In the subset of women with larger uteri and uterine
fibroids, Novasure alone is associated with higher failure
rate.12-14 In the current study, this drawback was over-
come by hysteroscopic guidance during the actual treat-
ment with Roller Ball. Using hysteroscopic Roller Ball
endometrial ablation as a definitive treatment also ensures
that trainees at teaching institutions will still have the
opportunity to learn the skill of Roller Ball ablation. A
single gynecologist performed all of these cases of Roller
Ball ablation in this study, removing operator bias with
respect to surgical technique.
Some of the limitations of this study include its retro-
spective nature, the nonrandomized allocation of pa-
tients, a relatively short duration of follow-up, the loss
of follow-up on half the patients by 32 mo, and the
potential for an increased depth of desiccation when 2
endometrial ablation techniques are used together. A
Table 1.
Mean Baseline Characteristics of the 2 Groups
Variable RB-Lupron [Mean (SD)]a RB-Novasure [Mean (SD)]a Significance (P)
Age (Years) 41.57 (4.93) 43.45 (6.52) .29
Gravida 3.61 (1.65) 2.68 (1.64) .08
Parity 2.74 (1.42) 2.05 (1.27) .11
BMIa (kg/m2) 31.91 (5.44) 31.44 (9.49) .85
Uterine Volume (mL) 396.18 (152.76) 514.92 (288.86) .35
Length of Procedure (mins) 42.65 (13.861) 47.94 (25.78) .46
Maximum follow-up Duration (days) 323.69 (281.53) 277.44 (214.77) .55
aRB-LupronGnRH agonists as medical endometrial preparation before Roller Ball ablation. RB-NovasureNovasure ablation as
mechanical endometrial preparation before Roller Ball ablation; SDStandard Deviation; BMIBody Mass Index.
Table 2.
Reasons for Large Uteri in the 2 Groups
RB-Luprona RB-Novasurea P Value
Fibroids 7/23 (30.4%) 8/20 (40%) .37
Adenomyosis 2/23 (8.7%) 1/20 (5%) .55
General Uterine
Enlargementb
0/23 (0%) 2/20 (10%) .21
aRB-LupronGnRH agonists as medical endometrial preparation
before Roller Ball ablation; RB-NovasureNovasure ablation as
mechanical endometrial preparation before Roller Ball ablation
bUterine enlargement not due to fibroids or adenomyosis.
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single operator performed all of the cases of Roller Ball
ablation, increasing the precision, but reducing the gen-
eralizability, of the findings. Nevertheless, this pilot
study provides important proof of the concept and aids
in designing a prospective study. A larger sample size,
and the participation of multiple operators to perform
the procedures will help overcome the limitation of low
generalizability of the study. We also recommend a
collection of quality of life scores prospectively to bet-
ter define patient satisfaction.
CONCLUSION
Our pilot study shows that the combination of both No-
vasure and Roller Ball ablation seems to be more effective
than preparation with GnRH agonist (Leuprolide acetate)
before Roller Ball ablation in terms of achieving persistent
amenorrhea, and significantly lower cramping or pelvic
pain in patients with large uteri. Also, the mean failure rate
(repeat ablation or hysterectomy for heavy bleeding or
persistent pain), although not statistically significant,
showed a trend towards a gradual, long-term higher fail-
Table 3.
Symptoms Evaluated Over the 3 Time Frames for the 2 Groups
Variable Follow-up RB-Lupron (%)a RB-Novasure (%)a P Value
Amenorrhea 3 months 10/22 (45.5) 16/20 (80) .02
3-12 months 10/17 (58.8) 13/15 (86.7) .08
12-32 months 4/9 (44.4) 8/8 (100) .02
Heavy bleeding 3 months 2/22 (9.1) 0/20 (0) .27
3-12 months 3/17 (17.6) 0/15 (0) .14
12-32 months 3/9 (33.3) 0/5 (0) .20
Cramps/Pelvic pain 3 months 6/22 (27.3) 0/20 (0) .01
3-12 months 6/17 (35.3) 0/15 (0) .02
12-32 months 7/9 (77.8) 1/7 (12.5) .01
Satisfaction 3 months 19/22 (86.4) 20/20 (100) .13
3-12 months 10/17 (58.8) 14/16 (87.5) .07
12-32 months 3/9 (33.3) 6/8 (75) .11
Failure (repeat ablation or hysterectomy) 3 months 1/21 (4.8) 0/20 (0) .51
3-12 months 1/16 (6.2) 2/16 (12.5) .50
12-32 months 5/9 (55.6) 0/8 (0) .02
aRB-LupronGnRH agonists as medical endometrial preparation before Roller Ball ablation. RB-NovasureNovasure ablation as
mechanical endometrial preparation before Roller Ball ablation.
Figure 1. Rate of amenorrhea in 2 groups. Figure 2. Satisfactory result postablation in 2 groups.
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ure rate for the RB-Lupron group, compared to the RB-
Novasure group (Figure 3).
To our knowledge, this is the first report of 2 endometrial
ablation techniques, from first and second-generations,
used in tandem to achieve a greater success rate. Although
the number of patients in each group is small, we did get
statistically significantly higher amenorrhea rates and
lower long-term failure rates with this combination. This is
only a pilot study, and it is not the current standard of care
to perform 2 endometrial ablation techniques together.
Further prospective studies are needed to evaluate the
effectiveness of Novasure as a method of endometrial
preparation prior to Roller Ball ablation.
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